Author

Ignazia Tusa

University of FlorenceORCID 0000-0002-9198-2630Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1

Frequent Co-Authors

Elisabetta RovidaiD· 2 shared Ylenia SfraganoiD· 2 shared Alessandro TubitaiD· 1 shared Alessio MenconiiD· 1 shared Atanasio PandiellaiD· 1 shared Azucena Esparı́s-OgandoiD· 1 shared Barbara A. SteccaiD· 1 shared Claudia Faundez VidiellaiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Elisabetta RovidaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintSep 18, 2026

ERK5 inhibition triggers CDK6 proteasomal degradation and enhances palbociclib efficacy in cancer cells

Claudia Faundez Vidiella, Ylenia Sfragano, Ignazia Tusa…·Elisabetta Rovida

This study shows that inhibiting ERK5 causes CDK6 degradation and enhances palbociclib's effectiveness in melanoma and endometrial cancer cells.

DOI 10.64898/2026.09.17.752291

humanexperimental assay

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJul 20, 2026

R-Ras coordinates reciprocal activation of ERK5 and ERK1/2 under single pathway inhibition in melanoma

Ignazia Tusa, Cosimo Mazzei, Dimitri Papini…·Elisabetta Rovida

This study shows that R-Ras coordinates reciprocal activation of ERK5 and ERK1/2 pathways in melanoma under MAPK inhibition, suggesting co-targeting R-Ras and MAPK signaling could improve therapy.

DOI 10.64898/2026.07.17.737152

humanbulk RNA-seq

𝕏 PostBluesky